DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for progressive non-fluent aphasia — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProgressive non-fluent aphasia maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for progressive non-fluent aphasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
presenilin 1 (PSEN1) — PSEN1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pc1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KCS · 2.4 Å · ligand 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE (PC1). Experimental structure, not a prediction.
What the evidence adds up to
Twenty-five people with chronic nonfluent aphasia received 24 sessions of Oral Reading for Language in Aphasia (ORLA) treatment, one to three times per week, after a no-treatment period. A small but significant mean change in the Western Aphasia Battery Aphasia Quotient was recorded from pre- to post-treatment. Medium effect sizes were seen across all severity levels for that quotient. The severe aphasia group showed medium effect sizes only on reading subtests, the moderate group only on discourse measures, and the mild-to-moderate group on both discourse and writing subtests. The authors concluded that low-intensity ORLA may improve language skills, with modality-specific outcomes differing by severity.
A qualitative study of four people with chronic aphasia and four partners identified five themes influencing whether therapy gains are maintained: beliefs about change, personal abilities, external support, engagement in real-life communication, and knowledge and service gaps. Participants reported limited understanding of why or how to maintain gains and described a lack of services to support maintenance. The study suggested that forming meaningful real-life communication routines might help, but noted that a lack of knowledge and services could hinder the ability to sustain therapeutic benefits.
A 2023 review of primary progressive aphasia—the language-led dementias—posed six unanswered questions, including whether syndromic diagnosis is useful, how to diagnose and track the disease better, whether brain pathology can be predicted, what the core pathophysiology is, and how best to treat it. The review proposed that linking proteinopathies to phenotypes might clarify the clinical complexity and guide future diagnostic tools and therapies, but it did not report any trial results or treatment outcomes for progressive non-fluent aphasia specifically.
What is still missing for progressive non-fluent aphasia is any controlled trial of a pharmacological or disease-modifying intervention. The ORLA study addressed chronic post-stroke aphasia, not the neurodegenerative form. The qualitative work highlighted gaps in patient and clinician knowledge about maintenance of gains, but no trial has tested a structured maintenance programme. The 2023 review made clear that even basic diagnostic and pathophysiological questions remain unresolved, and no therapy has been shown to slow progression in primary progressive aphasia. Funding for adequately powered, biomarker-stratified trials, and a consensus on how to measure meaningful endpoints in this rare population, are absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Seminars in Speech and Language · 2010 · 52 citations
Oral Reading for Language in Aphasia: Impact of Aphasia Severity on Cross-Modal Outcomes in Chronic Nonfluent Aphasia
AbstractThis study examined the efficacy of a treatment, Oral Reading for Language in Aphasia (ORLA), for individuals with chronic nonfluent aphasia of varying severity levels. With ORLA, the person with aphasia systematically and repeatedly reads sentences aloud, first in unison with the clinician and then independently. Following a period of no treatment, 25 individuals with chronic nonfluent aphasia received 24 sessions of ORLA, 1 to 3 times per week. A small, but significant mean change in the Western Aphasia Battery (WAB) Aphasia Quotient (AQ) was obtained from pre- to post-treatment. When subjects were divided by severity, medium effect sizes were obtained for all severity levels from pre- to post-treatment for the WAB AQ. Medium effect sizes were obtained for the severe aphasia group on the WAB reading subtests only, for the moderate aphasia group on the discourse measures only, and for the mild to moderate aphasia group on both the discourse and WAB writing subtests. Although more intensive therapy is preferred, individuals with chronic nonfluent aphasia may improve their language skills with low-intensity ORLA treatment, and differences in modality-specific outcomes may be anticipated based on the severity of the aphasia.
<i>“I’ve Got No Skills to Maintain – to Keep That Going”</i> : A Qualitative Study of People with Chronic Aphasia and Their Partners About Factors Contributing to the Maintenance of Aphasia Therapy Gains
AbstractBackground The maintenance of therapy gains is critical for successful aphasia rehabilitation, a topic often overlooked in both research and clinical practice. For some people with chronic aphasia, maintaining therapeutic gains can be challenging, potentially resulting in diminished communicative function over time. Furthermore, maintaining therapy gains may necessitate consistent, deliberate effort; however, little is known about the factors supporting this process. People living with chronic aphasia and their family members may provide critical insights into the behavioural factors that impact the maintenance of therapy gains. Understanding these factors will be crucial for developing long-lasting, effective aphasia interventions.Aim In this study, we explored the perspectives and practices of people with chronic aphasia and their partners concerning the maintenance of gains from therapy for post-stroke chronic aphasia.Methods & Procedures Eight in-depth, semi-structured interviews were conducted, involving four people with chronic aphasia and four partners. We employed inductive thematic data analysis to identify emergent themes.Outcomes & Results Five themes were identified that were perceived to influence the maintenance of gains made during aphasia rehabilitation. These were: 1) Beliefs about change: improvement, decline, and maintenance; 2) Personal abilities impact improvement and maintenance; 3) External support impacts improvement and maintenance; 4) Engaging in ongoing real-life communication impacts improvement and maintenance; and 5) Knowledge and services gaps in maintenance. The findings demonstrate the complexity and interaction of factors that potentially facilitate or hinder the maintenance of therapy gains in chronic aphasia.Conclusions People with chronic aphasia and their partners report having a limited understanding of the necessity and methods for maintaining therapy gains. They also describe a lack of services to support this. A lack of knowledge and services could hinder the ability to maintain therapeutic benefits. Our study also suggests various behavioural factors are involved in maintaining gains. Forming meaningful real-life communication routines may potentially optimise such gains. These findings highlight the necessity of placing maintenance at the heart of aphasia rehabilitation, informing future interventions and service development.
Greater South Information System · 2023 · 0 citations · open access
Primary progressive aphasia: six questions in search of an answer
AbstractHere, we review recent progress in the diagnosis and management of primary progressive aphasia-the language-led dementias. We pose six key unanswered questions that challenge current assumptions and highlight the unresolved difficulties that surround these diseases. How many syndromes of primary progressive aphasia are there-and is syndromic diagnosis even useful? Are these truly 'language-led' dementias? How can we diagnose (and track) primary progressive aphasia better? Can brain pathology be predicted in these diseases? What is their core pathophysiology? In addition, how can primary progressive aphasia best be treated? We propose that pathophysiological mechanisms linking proteinopathies to phenotypes may help resolve the clinical complexity of primary progressive aphasia, and may suggest novel diagnostic tools and markers and guide the deployment of effective therapies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
